{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:51:10Z","timestamp":1791269470701,"version":"4.1.0"},"reference-count":156,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-025-11455-5","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:27:30Z","timestamp":1772119650000},"page":"6697-6714","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advancement in peptide-based therapeutics for the treatment of type 2 diabetes mellitus: current progress and future prospects"],"prefix":"10.1007","volume":"30","author":[{"given":"Md Fahim","family":"Shahriar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janisa","family":"Kabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"11455_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107843","volume":"157","author":"P Saeedi","year":"2019","unstructured":"Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N et al (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045\u202f: results from the International Diabetes Federation Diabetes Atlas , 9 th edition. Diabetes Res Clin Pract 157:107843. https:\/\/doi.org\/10.1016\/j.diabres.2019.107843","journal-title":"Diabetes Res Clin Pract"},{"key":"11455_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.19","author":"RA Defronzo","year":"2015","unstructured":"Defronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ et al (2015) Type 2 diabetes mellitus. Nat Rev Dis Primers. https:\/\/doi.org\/10.1038\/nrdp.2015.19","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"11455_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrendo.2017.151","volume":"14","author":"Y Zheng","year":"2017","unstructured":"Zheng Y, Ley SH, Hu FB (2017) Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 14(2):88\u201398. https:\/\/doi.org\/10.1038\/nrendo.2017.151","journal-title":"Nat Rev Endocrinol"},{"key":"11455_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","volume":"7","author":"L Wang","year":"2022","unstructured":"Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G et al (2022) Therapeutic peptides\u202f: current applications and future directions. Signal Transduct Target Ther 7:48","journal-title":"Signal Transduct Target Ther"},{"key":"11455_CR5","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s12276-023-01016-x","volume":"55","author":"S Murugan","year":"2023","unstructured":"Murugan S, Vadevoo P, Gurung S, Lee H, Gunassekaran GR, Lee S (2023) Peptides as multifunctional players in cancer therapy. Exp Mol Med 55:1099\u20131109","journal-title":"Exp Mol Med"},{"key":"11455_CR6","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.bioactmat.2022.02.025","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, Zhang W, Zhao R, Zhang X (2022) Advances in oral peptide drug nanoparticles for diabetes mellitus treatment. Bioact Mater 15:392\u2013408. https:\/\/doi.org\/10.1016\/j.bioactmat.2022.02.025","journal-title":"Bioact Mater"},{"key":"11455_CR7","first-page":"1","volume":"3","author":"GF Lewis","year":"2022","unstructured":"Lewis GF, Brubaker PL (2022) The discovery of insulin revisited\u202f: lessons for the modern era. J Clin Investig 3:1\u20139","journal-title":"J Clin Investig"},{"key":"11455_CR8","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.1038\/emm.2016.6","volume":"48","author":"PV R\u00f6der","year":"2016","unstructured":"R\u00f6der PV, Wu B, Liu Y, Han W (2016) Pancreatic regulation of glucose homeostasis. Exp Mol Med 48:e219","journal-title":"Exp Mol Med"},{"issue":"1","key":"11455_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrm.2017.89","volume":"19","author":"RA Haeusler","year":"2017","unstructured":"Haeusler RA, Mcgraw TE, Accili D (2017) Biochemical and cellular properties of insulin receptor signalling. Nat Rev Mol Cell Biol 19(1):31\u201344. https:\/\/doi.org\/10.1038\/nrm.2017.89","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10365","key":"11455_CR10","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","volume":"400","author":"E Ahmad","year":"2022","unstructured":"Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ (2022) Type 2 diabetes. Lancet 400(10365):1803. https:\/\/doi.org\/10.1016\/S0140-6736(22)01655-5","journal-title":"Lancet"},{"key":"11455_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.134993","volume":"279","author":"S Fan","year":"2024","unstructured":"Fan S, Liu Q, Du Q, Zeng X, Wu Z, Pan D et al (2024) Multiple roles of food-derived bioactive peptides in the management of T2DM and commercial solutions\u202f: a review. Int J Biol Macromol 279:134993. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.134993","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"11455_CR12","first-page":"117","volume":"18","author":"D Accili","year":"2017","unstructured":"Accili D, Talchai SC, Kim-muller J, Cinti F, Ordelheide M, Kuo T et al (2017) When \u03b2-cells fail\u202f: lessons from dedifferentiation diabetes. Obes Metab 18(1):117\u2013122","journal-title":"Obes Metab"},{"key":"11455_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-021-00390-6","author":"DE James","year":"2021","unstructured":"James DE, St\u00f6ckli J, Birnbaum MJ (2021) The aetiology and molecular landscape of insulin resistance. Nat Rev Mol Cell Biol. https:\/\/doi.org\/10.1038\/s41580-021-00390-6","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"August","key":"11455_CR14","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.2337\/db20-1238","volume":"70","author":"Y Liu","year":"2021","unstructured":"Liu Y, He S, Zhou R, Zhang X, Yang S, Deng D et al (2021) Nuclear factor-Y in MOUSE Pancreatic B-Cells plays a crucial role in glucose homeostasis by regulating B-cell mass and insulin secretion. Diabetes 70(August):1703\u20131716","journal-title":"Diabetes"},{"issue":"7","key":"11455_CR15","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1007\/s10495-023-01854-0","volume":"28","author":"M Krishna","year":"2023","unstructured":"Krishna M, Sundhar P, Kunka M, Ramkumar M (2023) Dysfunctions, molecular mechanisms, and therapeutic strategies of pancreatic \u03b2\u2011cells in diabetes. Apoptosis 28(7):958\u2013976. https:\/\/doi.org\/10.1007\/s10495-023-01854-0","journal-title":"Apoptosis"},{"key":"11455_CR16","first-page":"629","volume":"118","author":"J Roth","year":"2021","unstructured":"Roth J, Sommerfeld O, Birkenfeld AL, Sponholz C, M\u00fcller UA, VonLoeffelholz C (2021) Blood sugar targets in surgical intensive care management and special considerations in patients with diabetes. Dtsch \u00c4rztebl Int 118:629","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"11455_CR17","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1021\/acs.jmedchem.7b00318","volume":"61","author":"A Henninot","year":"2018","unstructured":"Henninot A, Collins JC, Nuss JM (2018) The current state of peptide drug discovery\u202f: Back to the future? J Med Chem 61:1382\u20131414","journal-title":"J Med Chem"},{"key":"11455_CR18","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/nar\/gku892","volume":"43","author":"A Tyagi","year":"2015","unstructured":"Tyagi A, Tuknait A, Anand P, Gupta S, Sharma M, Mathur D et al (2015) CancerPPD\u202f: a database of anticancer peptides and proteins. Nucleic Acids Res 43:837\u2013843","journal-title":"Nucleic Acids Res"},{"key":"11455_CR19","first-page":"1","volume":"69","author":"SA Sebastian","year":"2023","unstructured":"Sebastian SA, Co EL, Mehendale M, Hameed M (2023) Insulin analogs in the treatment of type II diabetes and future perspectives. Dis-a-Mon 69:1\u201311","journal-title":"Dis-a-Mon"},{"key":"11455_CR20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s13181-024-01008-x","volume":"20","author":"S Marshall","year":"2024","unstructured":"Marshall S, Ryan E, Rivera J, Reynolds L, Atti S (2024) GLP-1 receptor agonist exposures are increasingly common and generally associated with mild symptoms\u202f: a single poison center experience. J Med Toxicol 20:278\u2013285","journal-title":"J Med Toxicol"},{"issue":"3","key":"11455_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ijcard.2013.11.007","volume":"170","author":"FJP Bernink","year":"2014","unstructured":"Bernink FJP, Timmers L, Beek AM, Diamant M, Roos ST, VanRossum AC et al (2014) Progression in attenuating myocardial reperfusion injury\u202f: an overview. Int J Cardiol [Internet] 170(3):261\u2013269. https:\/\/doi.org\/10.1016\/j.ijcard.2013.11.007","journal-title":"Int J Cardiol [Internet]"},{"key":"11455_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2023.107968","volume":"244","author":"C Furi\u00f3-novejarque","year":"2024","unstructured":"Furi\u00f3-novejarque C, Sala-mira I, D\u00edez J, Bondia J (2024) Computer methods and programs in biomedicine a model of subcutaneous pramlintide pharmacokinetics and its effect on gastric emptying\u202f: proof-of-concept based on populational data. Comput Methods Programs Biomed 244:107968. https:\/\/doi.org\/10.1016\/j.cmpb.2023.107968","journal-title":"Comput Methods Programs Biomed"},{"key":"11455_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2025.01.021","author":"A Moiz","year":"2025","unstructured":"Moiz A, Filion KB, Tsoukas MA, Yu HY (2025) Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation. Am J Med [Internet]. https:\/\/doi.org\/10.1016\/j.amjmed.2025.01.021","journal-title":"Am J Med [Internet]"},{"key":"11455_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-06053-9","author":"M Bl\u00fcher","year":"2023","unstructured":"Bl\u00fcher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM (2023) Dose\u2013response effects on HbA 1c and bodyweight reduction of survodutide, a dual glucagon\/GLP\u20111 receptor agonist, compared with placebo and open\u2011label semaglutide in people with type 2 diabetes\u202f: a randomised clinical trial. Diabetologia. https:\/\/doi.org\/10.1007\/s00125-023-06053-9","journal-title":"Diabetologia"},{"key":"11455_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.coph.2016.08.009","volume":"31","author":"BM Moran","year":"2016","unstructured":"Moran BM, Mckillop AM, Harte FPMO (2016) Glp-r I. ScienceDirect development of novel ligands for peptide GPCRs. Curr Opin Pharmacol 31:57\u201362. https:\/\/doi.org\/10.1016\/j.coph.2016.08.009","journal-title":"Curr Opin Pharmacol"},{"issue":"10085","key":"11455_CR26","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(17)30058-2","volume":"389","author":"S Chatterjee","year":"2017","unstructured":"Chatterjee S, Khunti K, Davies MJ (2017) Type 2 diabetes. Lancet 389(10085):2239\u20132251. https:\/\/doi.org\/10.1016\/S0140-6736(17)30058-2","journal-title":"Lancet"},{"key":"11455_CR27","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.cmet.2022.09.022","volume":"34","author":"R Sekar","year":"2022","unstructured":"Sekar R, Motzler K, Kwon Y, Miaczynska M, Herzig S, Zeigerer A (2022) Vps37a regulates hepatic glucose production by controlling glucagon receptor localization to endosomes ll Vps37a regulates hepatic glucose production by controlling glucagon receptor localization to endosomes. Cell metabol 34:1824\u20131842","journal-title":"Cell metabol"},{"key":"11455_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2025.01.010","author":"E Sadeghi","year":"2025","unstructured":"Sadeghi E, Rahmanipour E, Valsecchi N, Kapoor S, Vittoria M, Chhablani J (2025) An update on ocular effects of antidiabetic medications. Surv Ophthalmol. https:\/\/doi.org\/10.1016\/j.survophthal.2025.01.010","journal-title":"Surv Ophthalmol"},{"key":"11455_CR29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/B978-0-323-91817-6.00005-X","volume-title":"Dosage forms formulation developments and regulations","author":"J Jose","year":"2024","unstructured":"Jose J, Rajput A, Nikshitha M (2024) Regulatory affairs: historical overview, authorities, and role in drug approval [Internet]. In: Nayak AK, Sen KK (eds) Dosage forms formulation developments and regulations. Academic Press, New York, pp 99\u2013138"},{"key":"11455_CR30","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.otohns.2006.09.014","volume":"135","author":"EO Meltzer","year":"2006","unstructured":"Meltzer EO, Hamilos DL, Hadley JA, Lanza DC, Marple BF, Nicklas RA et al (2006) Developing guidance for clinical trials. Otolaryngol Head Neck Surg 135:S31\u2013S80","journal-title":"Otolaryngol Head Neck Surg"},{"key":"11455_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116124","volume":"265","author":"Y Wang","year":"2024","unstructured":"Wang Y, Yang P, Zhang Y, Sun J (2024) Synthesis and clinical application of new drugs approved by FDA in 2023. Eur J Med Chem 265:116124. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116124","journal-title":"Eur J Med Chem"},{"key":"11455_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117241","volume":"285","author":"Y Wang","year":"2025","unstructured":"Wang Y, Yang F, Wang B, Xie L, Chen W (2025) New FDA drug approvals for 2024\u202f: synthesis and clinical application. Eur J Med Chem 285:117241. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117241","journal-title":"Eur J Med Chem"},{"key":"11455_CR33","doi-asserted-by":"publisher","first-page":"7165","DOI":"10.3390\/molecules28207165","volume":"28","author":"G Rossino","year":"2023","unstructured":"Rossino G, Marchese E, Galli G, Verde F, Finizio M, Serra M et al (2023) Peptides as therapeutic agents\u202f: challenges and opportunities in the green transition era. Molecules 28:7165","journal-title":"Molecules"},{"key":"11455_CR34","doi-asserted-by":"publisher","first-page":"173153","DOI":"10.1016\/j.ejphar.2020.173153","volume":"879","author":"GS Ferreira","year":"2020","unstructured":"Ferreira GS, Veening-gri DH, Boon WPC, Hooijmans CR, Moors EHM, Schellekens H et al (2020) Comparison of drug efficacy in two animal models of type 2 diabetes: a systematic review and meta-analysis. Eur J Pharmacol 879:173153","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"11455_CR35","doi-asserted-by":"publisher","first-page":"302.e1","DOI":"10.1016\/j.amjmed.2011.07.033","volume":"125","author":"NR Desai","year":"2012","unstructured":"Desai NR, Shrank WH, Fischer MA, Avorn J, Liberman JN, Schneeweiss S et al (2012) Patterns of medication initiation in newly diagnosed diabetes mellitus\u202f: quality and cost implications. Am J Med 125(3):302.e1-302.e7. https:\/\/doi.org\/10.1016\/j.amjmed.2011.07.033","journal-title":"Am J Med"},{"key":"11455_CR36","first-page":"117","volume-title":"Evidence of clinical trials of cardiac outcomes on renal disease [Internet]. Cardiometabolic diseases","author":"VM Vargas","year":"2025","unstructured":"Vargas VM, Menon T, Castro M, Vijayaraghavan K (2025) Evidence of clinical trials of cardiac outcomes on renal disease [Internet]. Cardiometabolic diseases. Elsevier Inc, New York, pp 117\u2013128"},{"issue":"212","key":"11455_CR37","first-page":"315","volume":"1","author":"J Meece","year":"2019","unstructured":"Meece J (2019) Auditory and vestibular side effects of FDA-approved drugs for diabetes. Semin Hear 1(212):315\u2013325","journal-title":"Semin Hear"},{"issue":"3","key":"11455_CR38","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s13340-020-00475-1","volume":"12","author":"M Yamada","year":"2021","unstructured":"Yamada M, Suzuki J, Nakaya T, Ichikawa M, Yamamoto K, Imagawa M (2021) Comparative effects of insulin glulisine and lispro on postprandial plasma glucose and lipid profile in Japanese patients with type 2 diabetes mellitus. Diabetol Int 12(3):330\u2013335. https:\/\/doi.org\/10.1007\/s13340-020-00475-1","journal-title":"Diabetol Int"},{"key":"11455_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11886-017-0832-3","volume":"19","author":"A Kuhn","year":"2017","unstructured":"Kuhn A, Park J, Ghazi A, Aroda VR (2017) Intensifying treatment beyond monotherapy in type 2 diabetes mellitus: Where do newer therapies fit? Curr Cardiol Rep 19:25","journal-title":"Curr Cardiol Rep"},{"issue":"3","key":"11455_CR40","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.tcm.2021.12.008","volume":"33","author":"AM Chao","year":"2024","unstructured":"Chao AM, Tronieri JS, Amaro A, Wadden TA (2024) Semaglutide for the treatment of obesity. Trends Cardiovas Med 33(3):159\u2013166","journal-title":"Trends Cardiovas Med"},{"key":"11455_CR41","doi-asserted-by":"crossref","unstructured":"Shu Y, He X, Wu P, Liu Y, Ding Y (2022) Gastrointestinal adverse events associated with semaglutide\u202f: a pharmacovigilance study based on FDA adverse event reporting system.","DOI":"10.3389\/fpubh.2022.996179"},{"key":"11455_CR42","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1055\/a-2148-6321","volume":"39","author":"CD Humphrey","year":"2023","unstructured":"Humphrey CD, Lawrence AC (2023) Implications of ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg 39:719\u2013721","journal-title":"Facial Plast Surg"},{"issue":"1","key":"11455_CR43","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10439-022-03062-4","volume":"51","author":"L Desborough","year":"2023","unstructured":"Desborough L, Jaffe K, Hanna J, Ulloa J, Kaiserman K (2023) Transforming evidence generation for drug label changes\u202f: a case study. Ann Biomed Eng 51(1):137\u2013149","journal-title":"Ann Biomed Eng"},{"key":"11455_CR44","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.talanta.2016.08.067","volume":"161","author":"A Alshishani","year":"2016","unstructured":"Alshishani A, Makahleh A, Fang H, Adam E, Muhamad S, Saad B (2016) Ion-pair vortex assisted liquid-liquid microextraction with back extraction coupled with high performance liquid chromatography-UV for the determination of metformin in plasma. Talanta [Internet] 161:398\u2013404. https:\/\/doi.org\/10.1016\/j.talanta.2016.08.067","journal-title":"Talanta [Internet]"},{"issue":"4","key":"11455_CR45","doi-asserted-by":"publisher","first-page":"100497","DOI":"10.1016\/j.phyplu.2023.100497","volume":"3","author":"V Kshetrimayum","year":"2023","unstructured":"Kshetrimayum V, Devika K, Ghosh S, Kanti P (2023) Paris polyphylla Sm. extract enriched with diosgenin as an antidiabetic agent\u202f: in vitro and in vivo study. Phytomed Plus [Internet] 3(4):100497. https:\/\/doi.org\/10.1016\/j.phyplu.2023.100497","journal-title":"Phytomed Plus [Internet]"},{"issue":"6","key":"11455_CR46","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1371\/journal.pone.0100379","volume":"9","author":"Q Liu","year":"2014","unstructured":"Liu Q, Li S, Quan H, Li J (2014) Vitamin B12 status in metformin treated patients: systematic review. PLoS ONE 9(6):8\u201313","journal-title":"PLoS ONE"},{"key":"11455_CR47","first-page":"29","volume-title":"Structure and properties of insulin 2.1","author":"A Gupta","year":"2022","unstructured":"Gupta A (2022) Structure and properties of insulin 2.1. Elsevier, New York, pp 29\u201370"},{"issue":"3","key":"11455_CR48","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.anr.2016.06.001","volume":"10","author":"S Celik","year":"2016","unstructured":"Celik S, Pinar R (2016) Psychometric evaluation of a Turkish version of the Diabetes fear of self-injecting and self-testing questionnaire (D-FISQ). Asian Nurs Res (Korean Soc Nurs Sci) 10(3):195\u2013200. https:\/\/doi.org\/10.1016\/j.anr.2016.06.001","journal-title":"Asian Nurs Res (Korean Soc Nurs Sci)"},{"key":"11455_CR49","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.cca.2012.10.062","volume":"415","author":"R Yoshida","year":"2013","unstructured":"Yoshida R, Ohkubo K, Akehi Y, Harada S, Shinohara K (2013) Clinica Chimica Acta Clinical application of the different cross-reactivities of anti-insulin antibodies to insulin lispro to evaluate endogenous insulin secretion. Clin Chim Acta 415:250\u2013254. https:\/\/doi.org\/10.1016\/j.cca.2012.10.062","journal-title":"Clin Chim Acta"},{"key":"11455_CR50","first-page":"302","volume":"21","author":"G Bruno","year":"2011","unstructured":"Bruno G, De Micheli A, Frontoni S, Monge L, Diabetologia I (2011) Highlights from Italian standards of care for diabetes mellitus 2009\u20132010. Nutr Metab Cardiovas Dis 21:302\u2013314","journal-title":"Nutr Metab Cardiovas Dis"},{"key":"11455_CR51","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/B978-0-323-95719-9.00013-6","volume-title":"Anti-diabetic medicinal plants","author":"K Pundarikakshudu","year":"2024","unstructured":"Pundarikakshudu K, Shah PA, Patel MG (2024) A comprehensive review of Indian medicinal plants effective in diabetes management: current status and future prospects [Internet]. In: Naeem M, Aftab T (eds) Anti-diabetic medicinal plants. Elsevier Inc, New York, pp 3\u201373"},{"key":"11455_CR52","doi-asserted-by":"publisher","first-page":"122545","DOI":"10.1016\/j.lfs.2024.122545","volume":"343","author":"N Abraham","year":"2024","unstructured":"Abraham N, Kolipaka T, Pandey G, Negi M, Srinivasarao DA, Srivastava S (2024) Revolutionizing pancreatic islet organoid transplants\u202f: improving engraftment and exploring future frontiers. Life Sci 343:122545. https:\/\/doi.org\/10.1016\/j.lfs.2024.122545","journal-title":"Life Sci"},{"key":"11455_CR53","doi-asserted-by":"publisher","first-page":"100531","DOI":"10.1016\/j.rcsop.2024.100531","volume":"17","author":"A Alrowily","year":"2025","unstructured":"Alrowily A, Alfaraidy K, Almutairi S, Alamri A (2025) High-risk medication errors: insight from the UK National reporting and learning system. Explor Res Clin Soc Pharm 17:100531. https:\/\/doi.org\/10.1016\/j.rcsop.2024.100531","journal-title":"Explor Res Clin Soc Pharm"},{"issue":"52","key":"11455_CR54","doi-asserted-by":"publisher","first-page":"e36308","DOI":"10.1097\/MD.0000000000036308","volume":"102","author":"S Review","year":"2023","unstructured":"Review S (2023) Efficacy and safety of once-weekly basal insulin versus once-daily basal insulin in patients with type 2 diabetes. Medicine 102(52):e36308","journal-title":"Medicine"},{"key":"11455_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fgene.2023.1119181","volume":"14","author":"G Song","year":"2023","unstructured":"Song G, Zhang Y, Jiang Y, Zhang H, Gu W (2023) Signaling pathway of targeting the pancreas in the treatment of diabetes under the precision medicine big data evaluation system. Front Genet 14:1\u20139","journal-title":"Front Genet"},{"key":"11455_CR56","doi-asserted-by":"publisher","first-page":"106477","DOI":"10.1016\/j.pep.2024.106477","volume":"219","author":"D Peng","year":"2024","unstructured":"Peng D, Li Y, Si L, Zhu B, Wu P, Li Y et al (2024) A two-step method preparation of semaglutide through solid-phase synthesis and inclusion body expression. Protein Expr Purif 219:106477. https:\/\/doi.org\/10.1016\/j.pep.2024.106477","journal-title":"Protein Expr Purif"},{"key":"11455_CR57","unstructured":"Davies C (2025) Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide analogues in adults with type 2 diabetes mellitus for glycaemic control. 1 1\u201312"},{"key":"11455_CR58","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2147\/DMSO.S130834","volume":"10","author":"PA Levin","year":"2017","unstructured":"Levin PA, Kim SC (2017) Glucagon-like peptide-1 receptor agonists\u202f: a systematic review of comparative effectiveness research. Diabetes Metab Syndr Obes Targets Ther 10:123\u2013139","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"11455_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.111999","volume":"222","author":"Z Wen","year":"2025","unstructured":"Wen Z, Sun W, Wang H, Chang R, Wang J, Song C et al (2025) Comparison of the effectiveness and safety of GLP-1 receptor agonists for type 2 diabetes mellitus patients with overweight\/obesity\u202f: A systematic review and network meta-analysis. Diabetes Res Clin Pract 222:111999. https:\/\/doi.org\/10.1016\/j.diabres.2025.111999","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"11455_CR60","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dci24-0003","volume":"47","author":"DJ Drucker","year":"2024","unstructured":"Drucker DJ (2024) Obesity efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care 47(11):1873\u20131888","journal-title":"Diabetes Care"},{"key":"11455_CR61","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2174\/1573399812666151223093841","volume":"12","author":"SR Drab","year":"2016","unstructured":"Drab SR (2016) Glucagon-like peptide-1 receptor agonists for type 2 diabetes: a clinical update of safety and efficacy. Curr Diabetes Rev 12:403\u2013413","journal-title":"Curr Diabetes Rev"},{"key":"11455_CR62","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s12933-025-02874-7","volume":"24","author":"Z Arow","year":"2025","unstructured":"Arow Z, Hornik-lurie T, Hilu R, Giladi E, Arnson Y, Vaknin-assa H et al (2025) SGLT2 inhibitors and GLP-1 receptor agonists\u202f: impact on mortality in diabetic patients with cardiovascular disease. Cardiovasc Diabetol 24:353","journal-title":"Cardiovasc Diabetol"},{"key":"11455_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00576","author":"F Shi","year":"2018","unstructured":"Shi F, Li H, Cui M, Zhang Z, Gu Z, Liu X (2018) Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes\u202f: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2018.00576","journal-title":"Front Pharmacol"},{"key":"11455_CR64","volume-title":"Oral and injectable (non-insulin) pharmacological agents for type 2 diabetes","author":"R Rushakoff","year":"2014","unstructured":"Rushakoff R, Francisco S (2014) Oral and injectable (non-insulin) pharmacological agents for type 2 diabetes. Endotext, South Dartmouth (MA)"},{"key":"11455_CR65","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.molmet.2017.11.009","volume":"8","author":"CN Boyle","year":"2018","unstructured":"Boyle CN, Lutz TA, LeFoll C (2018) Amylin-its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity. Mol Metab [Internet] 8:203\u2013210. https:\/\/doi.org\/10.1016\/j.molmet.2017.11.009","journal-title":"Mol Metab [Internet]"},{"key":"11455_CR66","doi-asserted-by":"publisher","first-page":"320","DOI":"10.7570\/jomes21071","volume":"1","author":"B Dehestani","year":"2021","unstructured":"Dehestani B, Stratford NRS, Roux CW (2021) Amylin as a future obesity treatment. J Obes Metab Syndrome 1:320\u2013325","journal-title":"J Obes Metab Syndrome"},{"key":"11455_CR67","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.3390\/jcm11082207","volume":"11","author":"CN Boyle","year":"2022","unstructured":"Boyle CN, Lutz TA (2022) Mediators of amylin action in metabolic control. J Clin Med 11:2207","journal-title":"J Clin Med"},{"key":"11455_CR68","doi-asserted-by":"publisher","first-page":"47S","DOI":"10.1177\/0145721715607642","volume":"41","author":"L Hieronymus","year":"2015","unstructured":"Hieronymus L, Griffin S (2015) Role of amylin in type 1 and type 2 diabetes. Diabetes Educ 41:47S-56S","journal-title":"Diabetes Educ"},{"key":"11455_CR69","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.3390\/pharmaceutics16111442","volume":"16","author":"AM Karim","year":"2024","unstructured":"Karim AM (2024) Principles and biomedical applications of self-assembled peptides: potential treatment of type 2 diabetes mellitus. Pharmaceutics 16:1442","journal-title":"Pharmaceutics"},{"issue":"2","key":"11455_CR70","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.apsb.2021.08.003","volume":"12","author":"FJ Otero-","year":"2022","unstructured":"Otero- FJ, Bendicho-lavilla C, Seoane-vian I (2022) Fighting type 2 diabetes: formulation strategies for peptide-based therapeutics. Acta Pharm Sin 12(2):621\u2013636","journal-title":"Acta Pharm Sin"},{"key":"11455_CR71","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/bph.15446","volume":"179","author":"F Malik","year":"2022","unstructured":"Malik F, Li Z (2022) Non-peptide agonists and positive allosteric modulators of glucagon-like peptide-1 receptors: alternative approaches for treatment of type 2 diabetes. Br J Pharmacol 179:511\u2013525","journal-title":"Br J Pharmacol"},{"key":"11455_CR72","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1021\/acs.jnatprod.3c00886","volume":"87","author":"DJ Newman","year":"2024","unstructured":"Newman DJ (2024) Non-insulin-based drug entities used to treat diabetes type 2 disease (T2DM), based on natural products from all sources. J Nat Prod 87:629\u2013637","journal-title":"J Nat Prod"},{"key":"11455_CR73","first-page":"1","volume":"1801509","author":"AK Varanko","year":"2019","unstructured":"Varanko AK, Chilkoti A (2019) Molecular and materials engineering for delivery of peptide drugs to treat type 2 diabetes. Adv Healthc Mater 1801509:1\u201318","journal-title":"Adv Healthc Mater"},{"key":"11455_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph14080806","volume":"14","author":"J Blahova","year":"2021","unstructured":"Blahova J, Martiniakova M, Babikova M, Kovacova V, Mondockova V, Omelka R (2021) Pharmaceutical drugs and natural therapeutic products for the treatment of type 2 diabetes mellitus. Pharmaceuticals 14:1\u201332","journal-title":"Pharmaceuticals"},{"key":"11455_CR75","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.3390\/medicina57111209","volume":"57","author":"D Berillo","year":"2021","unstructured":"Berillo D, Yeskendir A, Zharkinbekov Z, Raziyeva K, Saparov A (2021) Peptide-based drug delivery systems. Medicina 57:1209","journal-title":"Medicina"},{"key":"11455_CR76","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/cbdd.12055","volume":"81","author":"DJ Craik","year":"2013","unstructured":"Craik DJ, Fairlie DP, Liras S, Price D (2013) The future of peptide-based drugs. Chem Biol Drug Des 81:136\u2013147","journal-title":"Chem Biol Drug Des"},{"key":"11455_CR77","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/pharmaceutics13050611","volume":"13","author":"D Vllasaliu","year":"2021","unstructured":"Vllasaliu D (2021) Non-invasive drug delivery systems. Pharmaceutics 13:10\u201312","journal-title":"Pharmaceutics"},{"key":"11455_CR78","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.4155\/tde.13.104","volume":"4","author":"BJ Bruno","year":"2013","unstructured":"Bruno BJ, Miller GD, Lim CS (2013) Basics and recent advances in peptide and protein drug delivery. Ther Deliv 4:1443\u20131467","journal-title":"Ther Deliv"},{"key":"11455_CR79","doi-asserted-by":"publisher","unstructured":"Li Z, Zhang Z, Yu B (2025) Unraveling the therapeutic landscape of approved non-peptide macrocycles. Acta Pharm Sin B [Internet]. Available from: https:\/\/doi.org\/10.1016\/j.apsb.2025.04.021","DOI":"10.1016\/j.apsb.2025.04.021"},{"key":"11455_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02107-5","author":"W Xiao","year":"2025","unstructured":"Xiao W, Jiang W, Chen Z (2025) Advance in peptide-based drug development\u202f: delivery platforms, therapeutics and vaccines. Signal Transduct Target Ther. https:\/\/doi.org\/10.1038\/s41392-024-02107-5. (December 2024)","journal-title":"Signal Transduct Target Ther"},{"key":"11455_CR81","doi-asserted-by":"publisher","unstructured":"Sawyer T, Hochman J, Addio SMD, Gindy ME (2019) Transport, stability and delivery considerations for the design of peptide drugs. https:\/\/doi.org\/10.1039\/9781788016445-00421","DOI":"10.1039\/9781788016445-00421"},{"issue":"0","key":"11455_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2021.1897043","volume":"0","author":"S Pradhan","year":"2021","unstructured":"Pradhan S, Prasad R, Sinha C, Sen P (2021) Molecular modeling of potent novel sulfonamide derivatives as non-peptide small molecule anti-COVID 19 agents. J Biomol Struct Dyn 0(0):1\u201319. https:\/\/doi.org\/10.1080\/07391102.2021.1897043","journal-title":"J Biomol Struct Dyn"},{"key":"11455_CR83","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00981-0","author":"T Min","year":"2020","unstructured":"Min T, Bain SC (2020) The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes\u202f: the SURPASS clinical trials. Diabetes Ther. https:\/\/doi.org\/10.1007\/s13300-020-00981-0","journal-title":"Diabetes Ther"},{"issue":"3","key":"11455_CR84","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.pcd.2025.03.008","volume":"19","author":"S Sokary","year":"2025","unstructured":"Sokary S, Bawadi H (2025) The promise of tirzepatide\u202f: a narrative review of metabolic benefits. Prim Care Diabetes 19(3):229\u2013237. https:\/\/doi.org\/10.1016\/j.pcd.2025.03.008","journal-title":"Prim Care Diabetes"},{"key":"11455_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2024.111758","volume":"213","author":"DS Popovic","year":"2024","unstructured":"Popovic DS, Patoulias D, Popovic LS, Karakasis P, Papanas N, Mantzoros CS (2024) Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus\u202f: a meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 213:111758. https:\/\/doi.org\/10.1016\/j.diabres.2024.111758","journal-title":"Diabetes Res Clin Pract"},{"key":"11455_CR86","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","volume":"18","author":"T Coskun","year":"2018","unstructured":"Coskun T, Sloop KW, Loghin C, Alsina-fernandez J, Urva S, Bokvist KB et al (2018) LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus\u202f: from discovery to clinical proof of concept. Mol Metab 18:3\u201314. https:\/\/doi.org\/10.1016\/j.molmet.2018.09.009","journal-title":"Mol Metab"},{"issue":"25","key":"11455_CR87","first-page":"1","volume":"8587","author":"L Guo","year":"2025","unstructured":"Guo L, Dong X, Ma J, Liu M, Lu Y, Wang H et al (2025) Articles efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS). Lancet Diabetes Endocrinol [Internet] 8587(25):1\u201315","journal-title":"Lancet Diabetes Endocrinol [Internet]"},{"key":"11455_CR88","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/oby.23612","volume":"31","author":"CW Roux","year":"2023","unstructured":"Roux CW, Chao AM, Ahmad NN, Zhang S, Aronne LJ, Machineni S et al (2023) Tirzepatide for the treatment of obesity\u202f: Rationale and design of the SURMOUNT clinical development program. Obesity 31:96\u2013110","journal-title":"Obesity"},{"issue":"1","key":"11455_CR89","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1124\/jpet.123.001679","volume":"388","author":"SP Kommera","year":"2024","unstructured":"Kommera SP, Kumar A, Chitkara D, Mittal A (2024) Pramlintide an adjunct to insulin therapy\u202f: challenges and recent progress in delivery. J Pharmacol Exp Ther 388(1):81\u201390. https:\/\/doi.org\/10.1124\/jpet.123.001679","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"11455_CR90","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.4158\/EP13477.OR","volume":"20","author":"K Herrmann","year":"2014","unstructured":"Herrmann K, Shan K, Brunell SC, Chen S (2014) Effects of pramlintide in patients with type 2 diabetes mellitus: an analysis using daily insulin dose tertiles. Endocr Pract 20(10):1070\u20131075","journal-title":"Endocr Pract"},{"issue":"October","key":"11455_CR91","doi-asserted-by":"publisher","first-page":"177095","DOI":"10.1016\/j.ejphar.2024.177095","volume":"985","author":"T Abdul-Rahman","year":"2024","unstructured":"Abdul-Rahman T, Roy P, Kamal F, Mueller-Gomez JL, Sarkar S, Garg N et al (2024) The power of three: retatrutide\u2019s role in modern obesity and diabetes therapy. Eur J Pharmacol [Internet]. 985(October):177095. https:\/\/doi.org\/10.1016\/j.ejphar.2024.177095","journal-title":"Eur J Pharmacol [Internet]."},{"key":"11455_CR92","doi-asserted-by":"publisher","unstructured":"Ramsbacher N. (2024) Retatrutide 579\u2013580 https:\/\/doi.org\/10.2337\/cd24-0062","DOI":"10.2337\/cd24-0062"},{"key":"11455_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119491","volume":"587","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang H, Ghosh D, Iii ROW (2020) Just how prevalent are peptide therapeutic products\u202f? A critical review. Int J Pharm 587:119491. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119491","journal-title":"Int J Pharm"},{"issue":"6","key":"11455_CR94","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1177\/193229681200600630","volume":"6","author":"F Ara\u00fajo","year":"2012","unstructured":"Ara\u00fajo F, Fonte P, Santos HA et al (2012) Oral delivery of glucagon-like peptide-1 and analogs: Alternatives for diabetes control? J Diabetes Sci Technol 6(6):1486\u20131497","journal-title":"J Diabetes Sci Technol"},{"key":"11455_CR95","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ejpb.2017.03.015","volume":"115","author":"R Ismail","year":"2017","unstructured":"Ismail R, Cs\u00f3ka I (2017) Novel strategies in the oral delivery of antidiabetic peptide drugs\u2013insulin , GLP 1 and its analogs. Eur J Pharm Biopharm 115:257\u2013267. https:\/\/doi.org\/10.1016\/j.ejpb.2017.03.015","journal-title":"Eur J Pharm Biopharm"},{"key":"11455_CR96","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.molimm.2024.03.009","volume":"171","author":"R Elahi","year":"2024","unstructured":"Elahi R, Nazari M, Mohammadi V, Esmaeilzadeh K (2024) IL-17 in type II diabetes mellitus (T2DM ) immunopathogenesis and complications\u202f; molecular approaches. Mol Immunol 171:66\u201376. https:\/\/doi.org\/10.1016\/j.molimm.2024.03.009","journal-title":"Mol Immunol"},{"key":"11455_CR97","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/ph15101283","volume":"15","author":"O Al Musaimi","year":"2022","unstructured":"Al Musaimi O, Lombardi L, Williams DR, Albericio F (2022) Strategies for improving peptide stability and delivery. Pharmaceuticals 15:1283","journal-title":"Pharmaceuticals"},{"key":"11455_CR98","doi-asserted-by":"publisher","first-page":"e16776","DOI":"10.1002\/aic.16776","volume":"66","author":"S Adhikari","year":"2019","unstructured":"Adhikari S, Leissa JA, Karlsson AJ (2019) Beyond function\u202f: engineering improved peptides for therapeutic applications. AIChE J 66:e16776","journal-title":"AIChE J"},{"key":"11455_CR99","doi-asserted-by":"publisher","unstructured":"Editors G, Beate P, Freie K, Berlin U, Schneider JP, Institutes N, et al. (2020) Peptide engineering meeting 8 Wiley special issue\u202f: peptide engineering meeting 8. 8\u201311. https:\/\/doi.org\/10.1002\/pep2.24131","DOI":"10.1002\/pep2.24131"},{"issue":"1","key":"11455_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12793\/tcp.2025.33.e3","volume":"33","author":"H Won","year":"2025","unstructured":"Won H, Cho J, Lee S (2025) Clinical development of oral semaglutide for the treatment of type 2 diabetes mellitus\u202f: focusing on early phase clinical trials. Transl Clin Pharmacol 33(1):1\u20139","journal-title":"Transl Clin Pharmacol"},{"key":"11455_CR101","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/dom.14922","volume":"25","author":"RRC New","year":"2023","unstructured":"New RRC, Chaudhari V, Michal MP, Sc BM, Travers GN, Gajanan BC (2023) Safety and efficacy of an oral insulin (Capsulin) in patients with early-stage type 2 diabetes\u202f: a dose-ranging phase 2b study. Diabetes Obes Metab 25:953\u2013960","journal-title":"Diabetes Obes Metab"},{"key":"11455_CR102","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/dom.14901","volume":"25","author":"R Eldor","year":"2023","unstructured":"Eldor R, Francis BH, Fleming A, Kidron M, Neutel J, Homer K et al (2023) Oral insulin (ORMD-0801) in type 2 diabetes mellitus\u202f: a dose-finding 12-week randomized placebo-controlled study. Diabetes Obes Metab 25:943\u2013952","journal-title":"Diabetes Obes Metab"},{"key":"11455_CR103","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0140-6736(25)01176-6","volume":"406","author":"A Gasiorek","year":"2025","unstructured":"Gasiorek A, Heydorn A, Gabery S, Hjerpsted JB, Kirkeby K, Kruse T et al (2025) Articles safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin\u202f: a first-in-human, phase 1. Lancet 406:135\u2013148","journal-title":"Lancet"},{"key":"11455_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-025-01125-9","author":"CS Walker","year":"2025","unstructured":"Walker CS, Aitken JF, Amarsingh GV, Zhang S, Cooper GJS (2025) Amylin\u202f: emergent therapeutic opportunities in overweight , obesity and diabetes mellitus. Nat Rev Endocrinol. https:\/\/doi.org\/10.1038\/s41574-025-01125-9","journal-title":"Nat Rev Endocrinol"},{"issue":"00","key":"11455_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17460441.2021.1942837","volume":"00","author":"X Lai","year":"2021","unstructured":"Lai X, Tang J, Elsayed MEH (2021) Recent advances in proteolytic stability for peptide, protein, and antibody drug discovery. Expert Opin Drug Discov [Internet] 00(00):1\u201316. https:\/\/doi.org\/10.1080\/17460441.2021.1942837","journal-title":"Expert Opin Drug Discov [Internet]"},{"issue":"4","key":"11455_CR106","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jsps.2014.06.004","volume":"24","author":"A Muheem","year":"2016","unstructured":"Muheem A, Shakeel F, Asadullah M, Anwar M, Mallick N, Kumar G et al (2016) A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives. Saudi Pharm J [Internet] 24(4):413\u2013428. https:\/\/doi.org\/10.1016\/j.jsps.2014.06.004","journal-title":"Saudi Pharm J [Internet]"},{"key":"11455_CR107","doi-asserted-by":"publisher","first-page":"106363","DOI":"10.1016\/j.ejps.2022.106363","volume":"181","author":"X Luo","year":"2023","unstructured":"Luo X, Chen H, Song Y, Qin Z, Xu L, He N (2023) Advancements, challenges and future perspectives on peptide-based drugs\u202f: focus on antimicrobial peptides. Eur J Pharm Sci 181:106363. https:\/\/doi.org\/10.1016\/j.ejps.2022.106363","journal-title":"Eur J Pharm Sci"},{"key":"11455_CR108","unstructured":"Rosania GR Overcoming cellular and systemic barriers to design the next wave of peptide therapeutics. In: GMT (ed)"},{"key":"11455_CR109","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11892-020-01309-9","volume":"20","author":"K Alexiadou","year":"2020","unstructured":"Alexiadou K, Tan TM (2020) Gastrointestinal peptides as therapeutic targets to mitigate obesity and metabolic syndrome. Curr Diabetes Rep 20:26","journal-title":"Curr Diabetes Rep"},{"key":"11455_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.149","author":"JJ Meier","year":"2016","unstructured":"Meier JJ, Rosenstock J (2016) Gastrointestinal safety of incretin therapies: Are we there yet? Nat Rev Gastroenterol Hepatol. https:\/\/doi.org\/10.1038\/nrgastro.2016.149","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"11455_CR111","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3390\/molecules23020414","volume":"23","author":"A Wardowska","year":"2018","unstructured":"Wardowska A (2018) Antibacterial peptides in dermatology-strategies for evaluation of allergic potential. Molecules 23:414","journal-title":"Molecules"},{"issue":"0","key":"11455_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1061186X.2021.1906884","volume":"0","author":"SS Timur","year":"2021","unstructured":"Timur SS, G\u00fcrsoy RN (2021) The role of peptide-based therapeutics in oncotherapy. J Drug Target 0(0):1\u201315. https:\/\/doi.org\/10.1080\/1061186X.2021.1906884","journal-title":"J Drug Target"},{"key":"11455_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2023.170939","volume":"161","author":"CJ Bailey","year":"2023","unstructured":"Bailey CJ, Flatt PR, Conlon JM (2023) An update on peptide-based therapies for type 2 diabetes and obesity. Peptides 161:170939. https:\/\/doi.org\/10.1016\/j.peptides.2023.170939","journal-title":"Peptides"},{"key":"11455_CR114","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.2337\/dci20-0039","volume":"43","author":"SI Taylor","year":"2020","unstructured":"Taylor SI (2020) The high cost of diabetes drugs: disparate impact on the most vulnerable patients. Diabetes Care 43:2330\u20132332","journal-title":"Diabetes Care"},{"key":"11455_CR115","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1162\/rest_a_00987","volume":"104","author":"F Gaessler","year":"2022","unstructured":"Gaessler F, Wagner S (2022) Patents, data exclusivity and the development of new drugs. Rev Econ Stat 104:571\u2013586","journal-title":"Rev Econ Stat"},{"key":"11455_CR116","first-page":"0","volume":"23","author":"A Patel","year":"2023","unstructured":"Patel A, Bhattacharjee A, Bhatt P (2023) Advancements in peptide-based therapeutics: design, synthesis and clinical applications. Biochem Cell Arch 23:0","journal-title":"Biochem Cell Arch"},{"key":"11455_CR117","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1021\/acs.joc.3c01494","volume":"89","author":"I Kekessie","year":"2024","unstructured":"Kekessie I, Wegner K, Martinez I, Kopach ME, White TD, Tom JK et al (2024) Process mass intensity (PMI): a holistic analysis of current peptide manufacturing processes informs sustainability in peptide synthesis. J Org Chem 89:4261\u20134282","journal-title":"J Org Chem"},{"key":"11455_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2020.100071","author":"MW Pennington","year":"2020","unstructured":"Pennington MW, Zell B, Bai CJ (2020) Commercial manufacturing of cGMP peptides spanning the gamut from neoantigen to commercial large-scale products. Med Drug Discov [Internet]. https:\/\/doi.org\/10.1016\/j.medidd.2020.100071","journal-title":"Med Drug Discov [Internet]"},{"key":"11455_CR119","doi-asserted-by":"publisher","first-page":"42457","DOI":"10.1039\/D0RA07204D","volume":"10","author":"V Martin","year":"2020","unstructured":"Martin V, Egelund PHG, Johansson H, Wojcik F, Pedersen DS (2020) Greening the synthesis of peptide therapeutics\u202f: an industrial perspective. RSC Adv 10:42457\u201342492","journal-title":"RSC Adv"},{"key":"11455_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules26154688","volume":"26","author":"C Luca De","year":"2021","unstructured":"Luca De C, Lievore G, Bozza D, Buratti A, Cavazzini A, Ricci A et al (2021) Downstream processing of therapeutic peptides by means of preparative liquid chromatography. Molecules 26:1\u201320","journal-title":"Molecules"},{"key":"11455_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2016.12.051","author":"A Larisa","year":"2016","unstructured":"Larisa A, Fu CW, Sau C, Andre LL, Yu LX (2016) Building parity between brand and generic peptide products: regulatory and scientific considerations for quality of synthetic peptides. Int J Pharm [Internet]. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.12.051","journal-title":"Int J Pharm [Internet]"},{"key":"11455_CR122","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jconrel.2022.02.011","volume":"345","author":"J Wu","year":"2022","unstructured":"Wu J, Sahoo JK, Li Y, Xu Q, Kaplan DL (2022) Challenges in delivering therapeutic peptides and proteins\u202f: a silk-based solution. J Control Release 345:176\u2013189. https:\/\/doi.org\/10.1016\/j.jconrel.2022.02.011","journal-title":"J Control Release"},{"issue":"1\u20132","key":"11455_CR123","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ijpharm.2015.01.044","volume":"481","author":"C Srinivasan","year":"2015","unstructured":"Srinivasan C, Siddiqui A, Korang-yeboah M, Khan MA (2015) Stability characterization and appearance of particulates in a lyophilized formulation of a model peptide hormone-humansecretin. Int J Pharm 481(1\u20132):104\u2013113. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.01.044","journal-title":"Int J Pharm"},{"key":"11455_CR124","doi-asserted-by":"publisher","first-page":"1809015","DOI":"10.1002\/adfm.201809015","volume":"29","author":"P Lin","year":"2019","unstructured":"Lin P, Chen K, Miao Y, Chen H, Lin K (2019) Phase-changeable nanoemulsions for oral delivery of a therapeutic peptide\u202f: toward targeting the pancreas for antidiabetic treatments using lymphatic transport. Adv Funct Mater 29:1809015","journal-title":"Adv Funct Mater"},{"key":"11455_CR125","first-page":"1","volume":"11","author":"MR Kim","year":"2019","unstructured":"Kim MR, Feng T, Zhang Q, Yin H, Chan E (2019) Co-encapsulation and co-delivery of peptide drugs via polymeric nanoparticles. Polymers 11:1\u201315","journal-title":"Polymers"},{"issue":"1","key":"11455_CR126","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/1932296819900258","volume":"15","author":"L Heinemann","year":"2020","unstructured":"Heinemann L, Braune K, Carter A, Zayani A, Kr\u00e4mer LA (2020) Insulin storage\u202f: a critical reappraisal. J Diabetes Sci Technol 15(1):147\u2013159","journal-title":"J Diabetes Sci Technol"},{"key":"11455_CR127","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jcis.2020.05.057","volume":"576","author":"J Liu","year":"2020","unstructured":"Liu J, Guo Z, Kordanovski M, Kaltbeitzel J, Zhang H, Cao Z et al (2020) Metal-organic frameworks as protective matrices for peptide therapeutics. J Colloid Interface Sci 576:356\u2013363","journal-title":"J Colloid Interface Sci"},{"key":"11455_CR128","unstructured":"Perrett S, Buell AK Biological and Nanomaterials. In: TPJK (ed)"},{"key":"11455_CR129","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3390\/biom14040479","volume":"14","author":"S Han","year":"2024","unstructured":"Han S, Won H (2024) Advancements in the application of ribosomally synthesized and post-translationally modified peptides (RiPPs). Biomolecules 14:479","journal-title":"Biomolecules"},{"issue":"2","key":"11455_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104300","volume":"30","author":"S Zhai","year":"2025","unstructured":"Zhai S, Liu T, Lin S, Li D, Liu H, Yao X et al (2025) Artificial intelligence in peptide-based drug design. Drug Discov Today 30(2):104300. https:\/\/doi.org\/10.1016\/j.drudis.2025.104300","journal-title":"Drug Discov Today"},{"key":"11455_CR131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom14101303","volume":"14","author":"N Nissan","year":"2024","unstructured":"Nissan N, Allen MC, Sabatino D (2024) Future perspective\u202f: harnessing the power of artificial intelligence in the generation of new peptide drugs. Biomolecules 14:1\u201313","journal-title":"Biomolecules"},{"key":"11455_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemolab.2022.104490","volume":"221","author":"S Zhang","year":"2022","unstructured":"Zhang S, Li X (2022) Pep-CNN\u202f: an improved convolutional neural network for predicting therapeutic peptides. Chemometr Intell Lab Syst 221:104490. https:\/\/doi.org\/10.1016\/j.chemolab.2022.104490","journal-title":"Chemometr Intell Lab Syst"},{"key":"11455_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116709","volume":"175","author":"Z Chen","year":"2024","unstructured":"Chen Z, Wang R, Guo J, Wang X (2024) The role and future prospects of artificial intelligence algorithms in peptide drug development. Biomed Pharmacother 175:116709. https:\/\/doi.org\/10.1016\/j.biopha.2024.116709","journal-title":"Biomed Pharmacother"},{"key":"11455_CR134","doi-asserted-by":"publisher","DOI":"10.1080\/14789450.2021.1962303","author":"L Perpetuo","year":"2021","unstructured":"Perpetuo L, Klein J, Ferreira R, Guedes S, Amado F, Leite-moreira A et al (2021) How can artificial intelligence be used for peptidomics\u202f? Expert Rev Proteomics [Internet]. https:\/\/doi.org\/10.1080\/14789450.2021.1962303","journal-title":"Expert Rev Proteomics [Internet]"},{"key":"11455_CR135","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090095","author":"J Smadbeck","year":"2014","unstructured":"Smadbeck J, Peterson MB, Zee BM, Garapaty S, Mago A, Lee C et al (2014) De novo peptide design and experimental validation of histone methyltransferase inhibitors. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0090095","journal-title":"PLoS ONE"},{"key":"11455_CR136","doi-asserted-by":"publisher","DOI":"10.1002\/ange.202213362","author":"L Chang","year":"2023","unstructured":"Chang L, Perez A (2023) Ranking peptide binders by affinity with alphafold. Angew Chem. https:\/\/doi.org\/10.1002\/ange.202213362","journal-title":"Angew Chem"},{"key":"11455_CR137","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.1038\/s41467-022-32007-7","volume":"13","author":"S Schmidt","year":"2022","unstructured":"Schmidt S (2022) ProtGPT2 is a deep unsupervised language model for protein design. Nat commun 13:4348","journal-title":"Nat commun"},{"key":"11455_CR138","doi-asserted-by":"publisher","first-page":"2406305","DOI":"10.1002\/advs.202406305","volume":"11","author":"X Wang","year":"2024","unstructured":"Wang X, Tang J, Liang H, Sun J, Dorje S, Peng B et al (2024) ProT-diff\u202f: a modularized and efficient approach to de novo generation of antimicrobial peptide sequences through integration of protein language model and diffusion model. Adv Sci 11:2406305","journal-title":"Adv Sci"},{"key":"11455_CR139","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fchem.2021.708364","volume":"9","author":"N Flores-holgu\u00edn","year":"2021","unstructured":"Flores-holgu\u00edn N, Frau J, Glossman-mitnik D, Quintana RM (2021) In silico pharmacokinetics, ADMET study and conceptual DFT analysis of two plant cyclopeptides isolated from Rosaceae as a computational peptidology approach. Front Chem 9:1\u201313","journal-title":"Front Chem"},{"key":"11455_CR140","doi-asserted-by":"publisher","unstructured":"Cabas-mora G, Sep\u00falveda-ya\u00f1ez J, Navarrete MA, Uribe-paredes R, Medina-ortiz D (2024) Peptide-based drug discovery through artificial intelligence\u202f: towards an autonomous design of therapeutic peptides. Briefings in Bioinformatics 25(4). https:\/\/doi.org\/10.1093\/bib\/bbae275","DOI":"10.1093\/bib\/bbae275"},{"issue":"2","key":"11455_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2022.103464","volume":"28","author":"K Sharma","year":"2023","unstructured":"Sharma K, Sharma KK, Sharma A, Jain R (2023) Peptide-based drug discovery\u202f: current status and recent advances. Drug Discov Today 28(2):103464. https:\/\/doi.org\/10.1016\/j.drudis.2022.103464","journal-title":"Drug Discov Today"},{"key":"11455_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122804","volume":"313","author":"X Wang","year":"2025","unstructured":"Wang X, Tian R, Liang C (2025) Biomimetic nanoplatform with microbiome modulation and antioxidant functions ameliorating insulin resistance and pancreatic \u03b2-cell dysfunction for T2DM management. Biomaterials 313:122804. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122804","journal-title":"Biomaterials"},{"key":"11455_CR143","first-page":"299","volume":"13","author":"EL Howard","year":"2025","unstructured":"Howard EL, Goens MM, Susta L, Patel A, Wootton SK (2025) Anti-drug antibody response to therapeutic antibodies and potential mitigation strategies. Biomed 13:299","journal-title":"Biomed"},{"key":"11455_CR144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0276423","volume":"18","author":"HF Dias","year":"2023","unstructured":"Dias HF, Mochizuki Y, Ku WM, Takahashi H (2023) Bacille calmette guerin (BCG) and prevention of types 1 and 2 diabetes\u202f: results of two observational studies. PLoS ONE 18:1\u201320","journal-title":"PLoS ONE"},{"key":"11455_CR145","first-page":"1","volume":"3","author":"X Li","year":"2020","unstructured":"Li X, Song Y (2020) Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy. J Hematol Oncol 3:1\u201314","journal-title":"J Hematol Oncol"},{"key":"11455_CR146","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.3390\/pharmaceutics16111486","volume":"16","author":"K Vrbnjak","year":"2024","unstructured":"Vrbnjak K (2024) Recent advances in peptide drug discovery\u202f: novel strategies and targeted protein degradation. Pharmaceutics 16:1486","journal-title":"Pharmaceutics"},{"issue":"1","key":"11455_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2022.103395","volume":"28","author":"N Guedeney","year":"2023","unstructured":"Guedeney N, Cornu M, Schwalen F, Kieffer C, Voisin-chiret AS (2023) Protac technology\u202f: a new drug design for chemical biology with many challenges in drug discovery. Drug Discov Today 28(1):103395. https:\/\/doi.org\/10.1016\/j.drudis.2022.103395","journal-title":"Drug Discov Today"},{"key":"11455_CR148","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.actbio.2021.08.046","volume":"135","author":"H Cheng","year":"2021","unstructured":"Cheng H, Cui Z, Guo S, Zhang X, Huo Y, Mao S (2021) Mucoadhesive versus mucopenetrating nanoparticles for oral delivery of insulin. Acta Biomater 135:506\u2013519","journal-title":"Acta Biomater"},{"key":"11455_CR149","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99","author":"J Soo","year":"2016","unstructured":"Soo J, Xu Q, Kim N, Hanes J, Ensign LM (2016) PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev [Internet] 99:28\u201351. https:\/\/doi.org\/10.1016\/j.addr.2015.09.012","journal-title":"Adv Drug Deliv Rev [Internet]"},{"issue":"0","key":"11455_CR150","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14728214.2019.1604684","volume":"0","author":"EJ Park","year":"2019","unstructured":"Park EJ, Choi J, Lee KC, Na DH (2019) Emerging PEGylated non-biologic drugs. Expert Opin Emerg Drugs [Internet] 0(0):1. https:\/\/doi.org\/10.1080\/14728214.2019.1604684","journal-title":"Expert Opin Emerg Drugs [Internet]"},{"key":"11455_CR151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/wnan.1897","volume":"15","author":"AK Andrianov","year":"2023","unstructured":"Andrianov AK (2023) Noncovalent PEGylation of protein and pepatide therapeutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol 15:1\u201321","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"11455_CR152","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/cbin.11108","volume":"43","author":"A Bolhassani","year":"2019","unstructured":"Bolhassani A (2019) Improvements in chemical carriers of proteins and peptides. Cell Biol Int 43:437\u2013452","journal-title":"Cell Biol Int"},{"issue":"2","key":"11455_CR153","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/17425247.2021.1825375","volume":"18","author":"S Maher","year":"2021","unstructured":"Maher S, Geoghegan C, Brayden DJ, Maher S, Geoghegan C, Intestinal DJB et al (2021) Expert opinion on drug delivery Intestinal permeation enhancers to improve oral bioavailability of macromolecules\u202f: reasons for low efficacy in humans reasons for low efficacy in humans. Expert Opin Drug Deliv [Internet]. 18(2):273\u2013300. https:\/\/doi.org\/10.1080\/17425247.2021.1825375","journal-title":"Expert Opin Drug Deliv [Internet]."},{"key":"11455_CR154","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.phrs.2018.09.003","volume":"137","author":"M Mirani","year":"2018","unstructured":"Mirani M, Favacchio G, Serone E, Lucisano G, Chiara M, Berra CC (2018) Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort. Pharmacol Res [Internet] 137:270\u2013279. https:\/\/doi.org\/10.1016\/j.phrs.2018.09.003","journal-title":"Pharmacol Res [Internet]"},{"key":"11455_CR155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpsyt.2023.1188101","volume":"14","author":"F Koniuszewski","year":"2023","unstructured":"Koniuszewski F, Vogel FD, Daji\u0107 I, Seidel T, Kunze M, Willeit M et al (2023) Navigating the complex landscape of benzodiazepine- and Z-drug diversity\u202f: insights from comprehensive FDA adverse event reporting system analysis and beyond. Front Psychiatry 14:1\u201323","journal-title":"Front Psychiatry"},{"key":"11455_CR156","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.clnu.2025.06.011","volume":"51","author":"K Nishida","year":"2025","unstructured":"Nishida K, Chr B, Dolladille C, Ebina T (2025) Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide\u202f: a vigibase study. Clin Nut 51:252\u2013265","journal-title":"Clin Nut"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11455-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-025-11455-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11455-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:02:38Z","timestamp":1791266558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-025-11455-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":156,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["11455"],"URL":"https:\/\/doi.org\/10.1007\/s11030-025-11455-5","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}